Erythropoietin therapy tied to hip-fracture risk in patients on dialysis
For patients on a high dose, it appears to be on a par with other well-known risk factors, authors say
There is a dose-dependent association between erythropoietin (EPO) treatment and risk of hip fractures in patients with end-stage renal disease (ESRD), a study shows.
EPO, widely used for management of anaemia in chronic kidney disease (CKD), is known to also promote bone remodelling, the authors note in the Journal of Bone and Mineral Research.
